---
title: >-
  Development of a Novel Longitudinal Observational Cohort of Adult and
  Pediatric Patients with Inflammatory Bowel Disease: TARGET-IBD.
description: >-
  Explore this publication on real-world evidence: Development of a Novel
  Longitudinal Observational Cohort of Adult and Pediatric Patients with
  Inflammatory…
date: '2018-01-01'
category: Publications
tags:
  - ACG
  - Poster Presentation
  - R&D
  - Care
  - Gastroenterology
  - IBD
  - Health System Partner
canonical_url: >-
  https://www.pedestalhealth.com/resources/publications/acg/development-of-a-novel-longitudinal-observational-cohort-of/
source: Pedestal Health
license: © 2026 Pedestal Health. All rights reserved.
slug: development-of-a-novel-longitudinal-observational-cohort-of
id: 3NlYgyi6Hl3u4qKsAVINxn
contentType: article
---

## Challenge

Advanced IBD therapy development lacked a large-scale, prospective, longitudinal real-world cohort with the depth of clinical, endoscopic, biomarker, and PRO data needed to generate comparative effectiveness, safety, and natural history evidence—the foundational gap that TARGET-IBD was designed to address.

## Solution

The TARGET-IBD registry was launched at ACG 2018 as a novel longitudinal observational cohort of adult and pediatric IBD patients at 35 US academic and community sites, designed for centralized medical record abstraction, quarterly PROs, and biospecimen collection with a target enrollment of 15,000 patients.

## Impact

Announcing the TARGET-IBD registry at ACG 2018 established the foundational real-world IBD evidence platform, initiating the investigator and pharma partner engagement that has since enabled 20+ publications and partnerships with AbbVie, Bristol Myers Squibb, Merck, and other IBD sponsors.